Beta interferons in clinically isolated syndromes - A meta-analysis

Division of Neurology and Epidemiology, Federal University of Bahia, Salvador, BA, Brazil.
Arquivos de Neuro-Psiquiatria (Impact Factor: 0.84). 04/2008; 66(1):8-10. DOI: 10.1590/S0004-282X2008000100003
Source: PubMed

ABSTRACT Beta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. After two years of follow-up, interferon beta decreased the risk of conversion to clinically definite MS 0.51[0.39-0.65], and delayed the time to diagnosis up to 367 days. Side-effects were mild and self limited. Our findings support the efficacy of early treatment with beta-interferon in reducing conversion to clinically defined MS in patients with clinically isolated syndromes.

14 Reads
  • Source
    • "In all of them, the episode was treated with high methylprednisolone doses, and the trials evaluated the risk of subsequent conversion to clinically definite MS, that is, the occurrence of a second acute episode, which was the primary endpoint in all studies. These studies represent evidence level 1 (recommendation grade A) and all showed that the administration of immunomodulating agents during CIS reduces the risk of a second demyelinating episode, without significant differences noted among the different types of immunomodulating agents [Clerico et al. 2008; Melo et al. 2008]. The criteria for treating CIS with disease-modifying agents are based on the identification of those patients at high risk of developing MS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management.Methods: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results.Results: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability.Conclusions: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.
    Therapeutic Advances in Neurological Disorders 11/2011; 4(6):349-60. DOI:10.1177/1756285611423560 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the Multiple Sclerosis Think Tank (Groupe de Réflexion sur la Sclérose en Plaques: GRESEP), composed of hospital neurologists involved in the management of patients with multiple sclerosis, is to provide recommendations in response to clinical questions that are raised when managing these patients. After work done on the themes on useful serum testing with suspected multiple sclerosis, as well as the detection and management of cognitive disorders early in the course of the disease, the subject of the present work is the early definition and early treatment of the disease. Following a systematic literature review, a RAND/UCLA appropriateness-derived method enabled consensual recommendations among a working group, a rating group and a reading group to be developed and formulated. Each recommendation is presented with the degree of consensus that it was accorded.
    Revue Neurologique 03/2012; 168(4):328-37. DOI:10.1016/j.neurol.2011.12.008 · 0.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interferon (IFN)-β is a front-line therapy for the treatment of the relapsing-remitting form of multiple sclerosis. However, its immunosuppressive mechanism of function remains incompletely understood. While it has been proposed that IFN-β suppresses the function of inflammatory myelin antigen-reactive T cells by promoting the release of immunomodulatory cytokines such as IL-27 from antigen-presenting cells (APCs), its direct effects on inflammatory CD4+ Th1 cells are less clear. Here, we establish that IFN-β inhibits mouse IFN-γ+ Th1 cell function in the absence of APCs. CD4+ T cells express the type I interferon receptor, and IFN-β can suppress Th1 cell proliferation under APC-free stimulation conditions. IFN-β-treated myelin antigen-specific Th1 cells are impaired in their ability to induce severe experimental autoimmune encephalomyelitis (EAE) upon transfer to lymphocyte-deficient Rag1-/- mice. Polarized Th1 cells downregulate IFN-γ and IL-2, and upregulate the negative regulatory receptor Tim-3, when treated with IFN-β in the absence of APCs. Further, IFN-β treatment of Th1 cells upregulates phosphorylation of Stat1, and downregulates phosphorylation of Stat4. Our data indicate that IFN-γ-producing Th1 cells are directly responsive to IFN-β and point to a novel mechanism of IFN-β-mediated T cell suppression that is independent of APC-derived signals.
    PLoS ONE 04/2015; 10(4):e0124802. DOI:10.1371/journal.pone.0124802 · 3.23 Impact Factor


14 Reads
Available from